Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.

Objective The main goal of dopamine cell replacement therapy in Parkinson disease (PD) is to provide clinical benefit mediated by graft survival with nigrostriatal reinnervation. We report a dichotomy between graft structure and clinical function in a patient dying 16 years following fetal nigral grafting.